EP0097648A1 - Sang entier synthetique et son procede de production - Google Patents

Sang entier synthetique et son procede de production

Info

Publication number
EP0097648A1
EP0097648A1 EP82902044A EP82902044A EP0097648A1 EP 0097648 A1 EP0097648 A1 EP 0097648A1 EP 82902044 A EP82902044 A EP 82902044A EP 82902044 A EP82902044 A EP 82902044A EP 0097648 A1 EP0097648 A1 EP 0097648A1
Authority
EP
European Patent Office
Prior art keywords
phase
whole blood
coacervate
volume
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP82902044A
Other languages
German (de)
English (en)
Other versions
EP0097648A4 (fr
Inventor
Charles S. Ecanow
Bernard Ecanow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neomed Corp
Original Assignee
Synthetic Blood Corp
Neomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Blood Corp, Neomed Inc filed Critical Synthetic Blood Corp
Publication of EP0097648A1 publication Critical patent/EP0097648A1/fr
Publication of EP0097648A4 publication Critical patent/EP0097648A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00—Photosensitive materials
    • G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047—Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471—Isoelectric point of gelatine

Abstract

Sang entier synthétique utile en tant que succédané du sang entier naturel des mammifères et son procédé de production. Le procédé de production permet d'obtenir une composition de matière comprenant un système coacervé à deux phases. Le système ci-décrit permet de reproduire avec succès sensiblement le système physico-chimique hétérogène à deux phases présent naturellement dans le sang entier des mammifères. Une phase du procédé de production est également décrite, permettant d'obtenir une composition de matière utile en tant que succédané de l'hématocryte naturel.
EP19820902044 1981-12-31 1982-05-21 Sang entier synthetique et son procede de production. Withdrawn EP0097648A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33606181A 1981-12-31 1981-12-31
US336061 1981-12-31

Publications (2)

Publication Number Publication Date
EP0097648A1 true EP0097648A1 (fr) 1984-01-11
EP0097648A4 EP0097648A4 (fr) 1984-10-18

Family

ID=23314398

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19820902044 Withdrawn EP0097648A4 (fr) 1981-12-31 1982-05-21 Sang entier synthetique et son procede de production.
EP82302620A Withdrawn EP0083469A3 (fr) 1981-12-31 1982-05-21 Sang complet synthétique et son procédé de préparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP82302620A Withdrawn EP0083469A3 (fr) 1981-12-31 1982-05-21 Sang complet synthétique et son procédé de préparation

Country Status (3)

Country Link
EP (2) EP0097648A4 (fr)
JP (1) JPS58502204A (fr)
WO (1) WO1983002228A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874742A (en) * 1981-01-05 1989-10-17 Synthetic Blood Corporation Synthetic whole blood and a process for preparing the same
EP0223906A3 (fr) * 1982-10-29 1989-02-01 Synthetic Blood Corporation Sang entier synthétique à base de gélatine et son procédé de fabrication
US4738952A (en) * 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
WO1985005035A1 (fr) * 1984-04-27 1985-11-21 Neomed, Inc. Substance de remplacement du sang humain et son procede de production
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4853370A (en) * 1984-04-27 1989-08-01 Synthetic Blood Corporation Substitute for human blood and a method of making the same
CA1272881A (fr) * 1985-08-29 1990-08-21 John D. Sheppard Methode de pretraitement thermochimique a basse temperature pour denoyer la tourbe
CA1318589C (fr) * 1986-08-14 1993-06-01 Bernard Ecanow Systeme d'administration de medicament
BR9917605A (pt) * 1999-08-12 2003-03-05 Alexandr V Asafov Composição substituta de plasma
AU2015243881B2 (en) * 2014-04-08 2021-08-19 Ginkgo Bioworks, Inc. Selective advantage in fermentation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742594A (en) * 1952-01-24 1955-12-30 Charles B Knox Gelatine Compan Preparation and purification of human serologically compatible protein derivatives for use as plasma extenders and products produced thereby
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4002739A (en) * 1975-02-18 1977-01-11 Warner-Lambert Company Soluble collagen
DE2940184A1 (de) * 1979-10-04 1981-04-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Kolloidloesung, die als blutersatz geeignet ist, und verfahren zu ihrer herstellung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB742594A (en) * 1952-01-24 1955-12-30 Charles B Knox Gelatine Compan Preparation and purification of human serologically compatible protein derivatives for use as plasma extenders and products produced thereby
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4002739A (en) * 1975-02-18 1977-01-11 Warner-Lambert Company Soluble collagen
DE2940184A1 (de) * 1979-10-04 1981-04-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Kolloidloesung, die als blutersatz geeignet ist, und verfahren zu ihrer herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8302228A1 *

Also Published As

Publication number Publication date
JPS58502204A (ja) 1983-12-22
EP0097648A4 (fr) 1984-10-18
EP0083469A2 (fr) 1983-07-13
WO1983002228A1 (fr) 1983-07-07
EP0083469A3 (fr) 1983-10-26

Similar Documents

Publication Publication Date Title
US4343797A (en) Synthetic whole blood and a method of making the same
US4963526A (en) Oral insulin and a method of making the same
US4439424A (en) Synthetic whole blood
US4794000A (en) Coacervate-based oral delivery system for medically useful compositions
Leese et al. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers
Jacob et al. Degradation of membrane phospholipids and thiols in peroxide hemolysis: Studies in vitamin E deficiency
Hebbel et al. Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders
EP0179904A1 (fr) Insuline administree par voie orale et son procede de preparation
FR2530953A1 (fr) Emulsion perfluoro-chimique utilisable comme sang artificiel et procede pour sa preparation
US4547490A (en) Synthetic whole blood and a method of making the same
EP0097648A1 (fr) Sang entier synthetique et son procede de production
US6277556B1 (en) Controlling donor blood characteristics
US4558032A (en) Synthetic whole blood substitute and a method of making the same
CA2764189C (fr) Utilisation de lcat pour traiter l'anemie et le dysfonctionnement des cellules de globules rouges
US4497829A (en) Process for preparing perfluorochemical emulsion artificial blood
EP0124527B1 (fr) Sang entier synthetique a base de gelatine et son procede de fabrication
JPS5835485B2 (ja) 酸素運搬輸液
US4738952A (en) Substitute for human blood and a method of making the same
US4596788A (en) Gelatin and lecithin based synthetic whole blood and a method of making the same
US4874742A (en) Synthetic whole blood and a process for preparing the same
Rosenthal et al. Effect of contrast media used in angiocardiography on hemoglobin-oxygen equilibrium
CA1224144A (fr) Sang entier synthetique et procede de preparation
AU583272B2 (en) Coacervate system synthetic whole blood substitute
CN106860446A (zh) 小儿复方氨基酸注射液19aa‑i 组合物及降低其氧含量的方法
DE19734279A1 (de) Wasserstoffhaltiges Medikament

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH LI LU NL SE

17P Request for examination filed

Effective date: 19831222

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEOMED CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SYNTHETIC BLOOD CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19901030

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ECANOW, CHARLES S.

Inventor name: ECANOW, BERNARD